background
pandem
influenza
emerg
april
spread
rapidli
broadli
world
addit
specif
antivir
agent
massiv
vaccin
thought
effect
way
control
transmiss
understand
prevaccin
statu
certain
risk
group
studi
compar
baselin
seropreval
antibodi
pandem
influenza
viru
among
hospit
staff
differ
contact
risk
gener
popul
method
total
serum
sampl
hospit
staff
control
serum
sampl
peopl
came
physic
checkup
control
group
collect
octob
novemb
massiv
vaccin
campaign
hospit
staff
divid
firstlin
risk
personnel
group
secondlin
risk
personnel
group
accord
potenti
contact
risk
hemagglutinationinhibit
hi
test
conduct
determin
individu
serolog
statu
seroposit
rate
spr
defin
proport
hi
titer
antibodi
influenza
viru
geometr
mean
titer
gmt
calcul
compar
among
differ
group
result
mean
age
sex
ratio
male
hospit
staff
control
group
year
year
respect
spr
antibodi
influenza
viru
hospit
staff
significantli
higher
control
group
vs
p
furthermor
spr
antibodi
influenza
viru
group
significantli
higher
group
vs
p
howev
gmt
antibodi
influenza
viru
hospit
staff
significantli
differ
control
group
p
conclus
spr
antibodi
pandem
viru
hospit
staff
higher
gener
popul
reflect
higher
contact
risk
prevaccin
surveil
immun
statu
differ
risk
group
may
help
priorit
group
vaccin
first
j
chin
med
assoc
pandem
novel
influenza
outbreak
pandem
start
unit
state
mexico
spread
worldwid
sinc
april
total
million
confirm
case
approxim
death
report
world
health
organ
sourc
novel
rearrang
viru
swine
avian
human
influenza
virus
young
peopl
suscept
infect
occasion
deterior
clinic
manifest
seropreval
antibodi
viru
hospit
staff
first
import
case
taiwan
appear
may
epidem
spread
commun
juli
healthcar
worker
accord
experi
sever
acut
respiratori
syndrom
sar
epidem
higher
risk
contract
diseas
belong
uniqu
risk
group
vaccin
campaign
novel
influenza
viru
nation
polici
protect
peopl
viral
attack
determin
prevaccin
preval
antibodi
level
novel
influenza
conduct
surveil
healthcar
personnel
medic
center
prepar
test
sera
follow
serum
mix
receptor
destroy
enzym
rde
denka
seiken
co
ltd
tokyo
japan
hour
remov
interf
nonspecif
receptor
reaction
stop
incub
mixtur
minut
phosphatebuff
salin
pb
mix
rdetreat
serum
gener
dilut
solut
next
pack
guinea
pig
red
blood
cell
gprbc
ad
solut
hour
remov
nonspecif
hemagglutin
activ
gprbc
suspens
prepar
follow
approxim
ml
guinea
pig
blood
obtain
thoroughli
mix
ratio
alsev
solut
anticoagul
gprbc
suspens
filtrat
steril
gauz
wash
pb
ph
time
dilut
pb
form
rbc
stock
suspens
rbc
work
suspens
prepar
hemagglutin
ha
hi
test
martindarbi
canin
kidney
mdck
cell
cultiv
fetal
calf
serum
biolog
industri
ltd
kibbutz
beit
haemek
israel
infect
influenza
viru
strain
kindli
provid
dr
yime
chen
viru
inactiv
use
cultur
supernat
serial
dilut
pb
ph
uplat
follow
ad
gprbc
suspens
well
plate
contain
equal
volum
serial
dilut
supernat
plate
cover
left
hour
room
temperatur
ha
titer
defin
reciproc
highest
dilut
show
complet
hemagglutin
gprbc
hi
test
conduct
mix
equal
volum
serial
dilut
rdetreat
serum
unit
viral
antigen
well
plate
gentl
shake
gprbc
ad
well
plate
plate
cover
left
hour
room
temperatur
hi
titer
defin
reciproc
highest
dilut
complet
inhibit
hemagglutin
gprbc
hi
titer
interpret
posit
geometr
mean
titer
gmt
defin
geometr
mean
posit
hi
titer
seroposit
rate
spr
defin
percentag
hi
titer
test
use
compar
differ
discret
variabl
student
test
mannwhitney
rank
sum
test
use
analyz
continu
variabl
age
hi
titer
appropri
analys
perform
spss
version
spss
inc
chicago
il
usa
p
valu
consid
statist
signific
total
hospit
staff
control
case
control
group
test
mean
age
sex
ratio
group
shown
tabl
hi
cutoff
valu
seroposit
spr
hospit
staff
significantli
higher
control
group
vs
p
tabl
delin
possibl
role
close
patient
contact
hospit
staff
divid
firstlin
risk
personnel
group
includ
doctor
divis
infecti
diseas
inpati
nurs
staff
emerg
depart
secondlin
risk
personnel
group
includ
gener
medic
doctor
laboratori
staff
administr
personnel
spr
group
significantli
higher
group
vs
p
tabl
statist
signific
differ
gmt
antibodi
influenza
viru
hospit
staff
control
group
vs
p
figur
also
signific
differ
group
vs
p
sinc
april
novel
rearrang
influenza
viru
origin
refer
swineorigin
influenza
viru
outbreak
emerg
mexico
unit
state
rapid
propag
almost
world
sever
month
issu
pandem
alarm
june
pandem
involv
countri
million
confirm
case
report
death
initi
case
mortal
rate
thought
high
approxim
mexico
appear
mortal
rate
season
influenza
case
mortal
rate
estim
taiwan
center
diseas
control
approxim
declin
case
mortal
rate
novel
pandem
like
due
rapid
viru
evolut
genet
analys
shown
signific
mutat
instead
stringent
surveil
infect
peopl
may
identifi
greater
number
mild
case
phenomenon
describ
anoth
swineorigin
influenza
outbreak
fort
dix
posit
case
diagnos
serolog
survey
case
clinic
symptom
death
result
consist
notion
serolog
surveil
seroposit
individu
identifi
certain
risk
group
hospit
staff
although
specif
antivir
agent
avail
treatment
gener
believ
effect
approach
vaccin
campaign
sever
studi
demonstr
efficaci
vaccin
prevent
mortal
hospit
recent
studi
indic
monoval
vaccin
immunogen
adult
children
advers
effect
associ
vaccin
mild
moder
initi
massiv
vaccin
campaign
imper
understand
seroepidemiolog
popul
tradit
hi
test
standard
evalu
antibodi
respons
influenza
vaccin
sinc
novel
influenza
viru
never
circul
among
peopl
previou
season
vaccin
offer
limit
crossprotect
spr
theoret
low
even
season
vaccin
howev
certain
risk
group
may
contract
diseas
myer
et
al
found
swine
worker
increas
risk
infect
swineorigin
influenza
viru
close
contact
healthcar
worker
suscept
infecti
diseas
seropreval
antibodi
viru
hospit
staff
result
support
notion
hospitalacquir
outbreak
report
sar
epidem
mild
pandem
hospit
issu
guidelin
use
person
protect
equip
wear
surgic
higherlevel
mask
glove
facial
protect
equip
selfreport
system
also
establish
identifi
symptomat
individu
accord
clinic
definit
set
taiwan
center
diseas
control
ie
fever
influenzalik
symptom
cough
headach
gener
malais
etc
exclus
ill
definit
diagnos
tonsil
studi
strikingli
high
spr
among
hospit
staff
especi
firstlin
worker
indic
symptom
mostli
mild
subclin
lack
signific
differ
gmt
unexpect
group
yet
vaccin
immun
status
presum
similar
howev
rel
low
gmt
level
indic
expos
individu
mild
vagu
symptom
develop
strong
immun
respons
compar
vaccin
usual
elicit
strong
immun
respons
recent
studi
pandem
viru
focus
clinic
manifest
symptomat
case
howev
scope
pandem
may
even
extens
admit
case
like
tip
iceberg
infect
individu
data
show
probabl
mild
even
subclin
symptom
sinc
infecti
control
polici
stringent
sar
epidem
may
prevent
sever
ill
reduc
amount
viral
exposur
person
protect
equip
may
suffici
virul
influenza
viru
equal
transmiss
power
one
limit
studi
distribut
age
sex
compar
hospit
staff
control
group
howev
subject
control
group
significantli
older
much
lower
spr
suggest
hospit
staff
could
even
higher
risk
infect
select
agematch
basi
anoth
limit
studi
includ
questionnair
obtain
recent
contact
travel
histori
studi
subject
process
establish
vaccin
polici
group
vaccin
first
imper
determin
rel
risk
contract
diseas
certain
risk
group
data
indic
hospit
staff
vaccin
soon
possibl
influenza
viru
high
risk
contract
addit
prevaccin
surveil
healthcar
worker
may
serv
target
group
earli
seroepidemiolog
chang
new
emerg
infecti
diseas
may
detect
vaccin
efficaci
evalu
furthermor
alreadi
develop
protect
antibodi
pandem
viru
whether
booster
dose
vaccin
need
debat
given
rel
high
proport
certain
group
may
alreadi
develop
protect
antibodi
given
mild
natur
pandem
viru
pro
con
massiv
vaccin
campaign
deserv
investig
